Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Edward, Mckenna"'
Autor:
Hussein Tawbi, Tu My To, Karen Bartley, Natalia Sadetsky, Elizabeth Burton, Lauren Haydu, Edward McKenna
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 139-150 (2022)
Abstract Background Patients with melanoma and central nervous system (CNS) metastases have poor survival outcomes. We investigated real‐world treatment patterns and overall survival (OS) of patients with melanoma and CNS metastases. Methods A retr
Externí odkaz:
https://doaj.org/article/5fdbb62efc8440b08eab1d866137a0aa
Autor:
Yavor Dragostinov, Daney Harðardóttir, Peter Edward McKenna, David A. Robb, Birthe Nesset, Muneeb Imtiaz Ahmad, Marta Romeo, Mei Yii Lim, Chuang Yu, Youngkyoon Jang, Mohammed Diab, Angelo Cangelosi, Yiannis Demiris, Helen Hastie, Gnanathusharan Rajendran
Publikováno v:
Methods in Psychology, Vol 7, Iss , Pp 100103- (2022)
This study implemented a Delphi Method; a systematic technique which relies on a panel of experts to achieve consensus, to evaluate which questionnaire items would be the most relevant for developing a new Propensity to Trust scale. Following an init
Externí odkaz:
https://doaj.org/article/cdc44e4c078a49db95c8bffce0e97337
Publikováno v:
Methods in Psychology, Vol 7, Iss , Pp 100101- (2022)
Investigating a developmental disorder (DD) must consider three questions: 1) Who are you measuring? 2) How are you measuring? and 3) What are you measuring? The decisions made – from selecting an appropriate comparison group and deciding what to m
Externí odkaz:
https://doaj.org/article/7386be80ebce4a218fd8d400ab4b7296
Autor:
Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. Methods Recur
Externí odkaz:
https://doaj.org/article/26a1f6c183d346e98b0aeea13c640df3
Autor:
Aleksandar Sekulic, Simon Yoo, Ragini Kudchadkar, Julie Guillen, Gary Rogers, Anne Lynn S. Chang, Scott Guenthner, Bernard Raskin, Keith Dawson, Yong Mun, Laura Chu, Edward McKenna, Mario Lacouture
Publikováno v:
PLoS ONE, Vol 17, Iss 1 (2022)
Background Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials. The purpos
Externí odkaz:
https://doaj.org/article/17287a88382e40d780f87974d4f15a98
Autor:
Ralf Gutzmer, Caroline Robert, Thomas Eigentler, Qian Zhu, Helen Gogas, Grant McArthur, Paolo Ascierto, Daniil Stroyakovskiy, Svetlana Protsenko, Rodrigo Pereira, Lev Demidov, Georgy Moiseevich Manikhas, Haocheng Li, Edward McKenna, Virginia McNally
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/e85259d827c149f2a0ae7f4ca214a744
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and
Externí odkaz:
https://doaj.org/article/369c8eef082e487e8b1ee700e6160944
Autor:
Ronald E, Cox, Marie, Parish, Carolyn, Oxencis, Edward, Mckenna, Bicky, Thapa, Sakti, Chakrabarti
Publikováno v:
World Journal of Clinical Oncology. 13:599-608
There are currently three coronavirus disease 2019 (COVID-19) vaccines approved by the United States Food and Drug Administration to prevent coronavirus infection. However, robust data are unavailable on the adverse events of the vaccines in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa62df4ef25b42dd383d77832f40a6fe
https://doi.org/10.5306/wjco.v13.i7.599
https://doi.org/10.5306/wjco.v13.i7.599
Autor:
Daniel M. Halperin, Gauri R. Varadhachary, James C. Yao, Scott E. Woodman, Keith F. Fournier, Scott Kopetz, Ajaykumar C. Morani, Walter C. Darbonne, Katja Schulze, Shannon Dervin, Cindy Yun, Edward McKenna, Patricia Cortazar, Patrick Hwu, Armeen Mahvash, Anuj Verma, Pamela Villalobos, Honglei Chen, Edwin R. Parra Cuentas, Luisa M. Solis Soto, Dipen M. Maru, Andrew P. Futreal, Ignacio I. Wistuba, Paul F. Mansfield, Christopher P. Scally, Richard E. Royal, Seema Prasad, Anais Malpica, Szu-Chin Fu, Mark Knafl, Anneleis F. Willett, Michael J. Overman, Suyu Liu, Kanwal Raghav
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::810c1697e03dca3033be01a2d214aa5c
https://doi.org/10.1158/2159-8290.c.6549433.v1
https://doi.org/10.1158/2159-8290.c.6549433.v1
Autor:
Michael B Atkins, Cristina Julian, Matthew H Secrest, Janet Lee, Ana M Abajo-Guijarro, Edward McKenna
Publikováno v:
Future Oncology. 18:2233-2245
Aim: To assess overall survival (OS) in patients with advanced BRAF-mutant melanoma by first-line (1L) targeted therapy (TT) or checkpoint inhibitor (CPI) use, second-line (2L) TT or CPI use, and treatment sequence. Patients & methods: Advanced BRAF-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3c1efe15351e72e0adef3b72a60e42e
https://doi.org/10.2217/fon-2021-1536
https://doi.org/10.2217/fon-2021-1536